I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
3.480
-0.040 (-1.14%)
At close: Sep 26, 2025, 4:00 PM EDT
3.482
+0.002 (0.05%)
After-hours: Sep 26, 2025, 7:37 PM EDT
I-Mab Employees
I-Mab had 32 employees as of December 31, 2024. The number of employees decreased by 188 or -85.45% compared to the previous year.
Employees
32
Change (1Y)
-188
Growth (1Y)
-85.45%
Revenue / Employee
n/a
Profits / Employee
-$1,156,594
Market Cap
400.62M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMAB News
- 17 days ago - I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market - Seeking Alpha
- 4 weeks ago - I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - GlobeNewsWire
- 5 weeks ago - I-Mab to Participate in September Investor Conferences - GlobeNewsWire
- 2 months ago - Everest Medicines Expands Strategic Investment in I-MAB - PRNewsWire
- 2 months ago - I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health - GlobeNewsWire
- 3 months ago - I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 - GlobeNewsWire
- 3 months ago - I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - GlobeNewsWire